Study Summary
This trial will test if using a PET/CT scan with NETSPOT can more accurately find neuroendocrine tumors, making it easier to remove them during surgery.
Eligible Conditions
- Pancreatic Neuroendocrine Tumors (NETs)
- Carcinoid Syndrome
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: From baseline through 12 months
Month 12
Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement
Week 3
Comparison of intraoperative findings to preoperative PET scan findings
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Gallium Dotatate
1 of 1
Experimental Treatment
12 Total Participants · 1 Treatment Group
Primary Treatment: Gallium Dotatate · No Placebo Group · Phase < 1
Gallium Dotatate
Drug
Experimental Group · 1 Intervention: Gallium Dotatate · Intervention Types: DrugTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from baseline through 12 months
Who is running the clinical trial?
University of Alabama at BirminghamLead Sponsor
1,435 Previous Clinical Trials
2,229,222 Total Patients Enrolled
Sushanth Reddy, MDPrincipal Investigator - University of Alabama at Birmingham
Birmingham VA Medical Center
University Of Alabama School Of Medicine (Medical School)
University Of Ky A B Chandler (Residency)
Eligibility Criteria
Age 19 - 100 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You are mentally competent to provide informed consent to participate in the study.
You have a tumor with a pre-operative 68Gallium-DOTATATE scan.
You must be at least 19 years of age to participate in this study
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments